ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 68 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is 38.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $195,000 | -51.2% | 396,104 | 0.0% | 0.19% | -55.4% |
| Q2 2016 | $400,000 | +47.6% | 396,104 | 0.0% | 0.42% | +66.3% |
| Q1 2016 | $271,000 | -42.9% | 396,104 | 0.0% | 0.25% | -12.2% |
| Q4 2015 | $475,000 | -64.4% | 396,104 | -34.4% | 0.29% | -63.2% |
| Q3 2015 | $1,334,000 | -5.2% | 603,740 | 0.0% | 0.78% | +21.9% |
| Q2 2015 | $1,407,000 | +10.4% | 603,740 | 0.0% | 0.64% | +17.9% |
| Q1 2015 | $1,274,000 | -5.8% | 603,740 | 0.0% | 0.54% | +41.1% |
| Q4 2014 | $1,352,000 | -15.5% | 603,740 | 0.0% | 0.38% | -59.9% |
| Q3 2014 | $1,600,000 | -28.4% | 603,740 | 0.0% | 0.96% | -7.8% |
| Q2 2014 | $2,234,000 | -68.5% | 603,740 | 0.0% | 1.04% | -73.5% |
| Q1 2014 | $7,088,000 | +40.8% | 603,740 | 0.0% | 3.91% | +3.1% |
| Q4 2013 | $5,035,000 | -10.2% | 603,740 | 0.0% | 3.79% | +18.7% |
| Q3 2013 | $5,609,000 | -5.2% | 603,740 | 0.0% | 3.20% | -29.8% |
| Q2 2013 | $5,917,000 | – | 603,740 | – | 4.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 396,104 | $400,000 | 0.42% |
| Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
| EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
| Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
| A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
| Renaissance Technologies | 876,100 | $876,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
| Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |